AxoGen
AxoGen (NASDAQ: AXGN) develops and commercializes FDA-regulated biologic and medical device products for surgical peripheral nerve repair, serving hospitals, surgeons, and patients across Extremities, Breast Reconstruction, and Oral Maxillofacial/Head & Neck markets in the United States.
- Company typePublic
- Founded2002
- HeadquartersAlachua, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What AxoGen does
AxoGen (NASDAQ: AXGN) is a publicly traded biotechnology and medical device company founded in 2002 and headquartered in Alachua, Florida (with corporate leadership in Tampa, FL). The company develops and commercializes surgical technologies for peripheral nerve repair, addressing nerve discontinuities, compression injuries, and neuroma prevention across three primary commercial markets: Extremities, Breast Reconstruction (including the Resensation technique), and Oral Maxillofacial/Head & Neck procedures. The company operates an FDA-regulated 24/7 tissue processing facility in Vandalia, Ohio, and a global distribution facility in Burleson, Texas, with wholly-owned subsidiaries in Germany for European market reach.
The product portfolio centers on two technology platforms: (1) Avance, an acellular nerve allograft that received FDA Biologics License Application approval on December 3, 2025, becoming the first and only FDA-approved biologic therapeutic for peripheral nerve discontinuities with 12 years of market exclusivity; and (2) the Axoguard family of porcine small intestine submucosa (SIS)-based devices, including the Nerve Connector (for gaps up to 5mm), Nerve Protector, HA+ Nerve Protector (with resorbable hyaluronate-alginate coating), and Nerve Cap (for neuroma prevention). The portfolio is rounded out by Avive+ Soft Tissue Matrix, a multi-layer amnion barrier. The company holds ISO 13485 certification, AATB accreditation, and multiple state tissue bank licenses.
AxoGen generates revenue through direct field sales to hospitals, ambulatory surgical centers, and surgeons across the United States. Products are sold one-time per procedure via surgeon-directed purchasing, with pricing determined by hospital procurement and insurance coverage rather than public disclosure. The company partners with Musculoskeletal Clinical Regulatory Advisers (MCRA) for coding and reimbursement support, and reports approximately 86% domestic covered lives insured following Cigna and Elevance Health positive coverage decisions. Full-year 2025 revenue was $225.2 million (20.2% YoY growth), with Q1 2026 reaching $61.5 million (26.6% YoY growth) and 2026 guidance of at least $270 million. The company became debt-free in January 2026 following a $133.3 million public offering.
AxoGen firmographics
Firmographics- Name
- AxoGen
- Legal name
- Axogen Corporation
- Website
- https://axogeninc.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- AxoGen (NASDAQ: AXGN) develops and commercializes FDA-regulated biologic and medical device products for surgical peripheral nerve repair, serving hospitals, surgeons, and patients across Extremities, Breast Reconstruction, and Oral Maxillofacial/Head & Neck markets in the United States.
- Ownership category
- akta.pro rank
AxoGen industry classification
Industry- Product category
- Surgical Nerve Repair Products
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
Keywords
Where AxoGen is headquartered
LocationHeadquarters
- HQ city
- Alachua
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
AxoGen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Medical Device and Biologic Product Sales: Revenue generated from the sale of peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Products sold directly to hospitals and surgical facilities for use in nerve repair procedures. Revenue is one-time per procedure with recurring account relationships.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
AxoGen product offering
Product offeringCore offering
AxoGen develops, manufactures, and markets a portfolio of medical devices and biologic products for the surgical repair of peripheral nerve injuries. Its offerings include the FDA-approved Avance acellular nerve allograft and the Axoguard family of porcine small intestine submucosa (SIS)-based nerve connectors, protectors, and caps, plus the Avive+ Soft Tissue Matrix. Products are sold to hospitals, ambulatory surgical centers, and surgeons for use in extremity, breast reconstruction, and oral maxillofacial/head & neck nerve repair procedures.
Product overview
AxoGen offers a comprehensive suite of surgical products for peripheral nerve repair. The portfolio includes Avance (FDA-approved biologic nerve allograft), the Axoguard family of SIS-based devices (Nerve Connector, Nerve Protector, HA+ Nerve Protector, Nerve Cap), and Avive+ Soft Tissue Matrix. These products address the full spectrum of nerve repair scenarios: Avance provides an acellular nerve scaffold for bridging gaps, the Nerve Connector enables tension-free coaptation for small gaps, the Nerve Protectors wrap and shield injured nerves from soft tissue attachments, the Nerve Cap prevents neuroma formation, and Avive+ provides soft tissue separation. The company transitioned from a medical device platform to a regulated biologics business following FDA approval of Avance in December 2025.
Differentiator
Problem solved
Functional benefit
Brands
- Avance: FDA-approved acellular nerve allograft for peripheral nerve discontinuities
- Axoguard
- Avive+
- Resensation
Products and services
- Avance Acellular Nerve Allograft FDA-approved acellular nerve allograft serving as a biologic scaffold for nerve regrowth across peripheral nerve discontinuities in patients aged one month and older. Indicated for surgical nerve repair procedures performed by peripheral nerve, trauma, breast reconstruction, and oral maxillofacial surgeons.
- Axoguard Nerve Connector Porcine small intestine submucosa (SIS) matrix designed for Connector Assisted Repair of transected nerves with gaps up to 5mm, alleviating tension at the repair site and aiding nerve end alignment for peripheral nerve surgeons.
- Axoguard Nerve Protector Porcine small intestine submucosa (SIS) implant with a pre-curled design for circumferential wrapping of injured or compressed nerves, minimizing soft tissue attachments during healing for use by peripheral nerve and reconstructive surgeons.
- Axoguard HA+ Nerve Protector SIS-based nerve protector with a short-term resorbable hyaluronate-alginate gel coating designed to enhance nerve gliding and minimize soft tissue attachments during the critical healing phase for peripheral nerve and reconstructive surgeons.
- Axoguard Nerve Cap Porcine small intestine submucosa (SIS) matrix with proprietary bifurcation design intended to reduce the development of symptomatic or painful neuromas by minimizing pathological axon interaction, for use in neuroma prevention procedures.
- Avive+ Soft Tissue Matrix Multi-layer amnion intended for use as a soft tissue barrier in acutely inflamed or irritated environments, resorbing over 16 weeks to provide barrier function through the critical healing phase for surgical applications.
Quantifiable outcome
- 23.5% year-over-year revenue growth in Q3 2025
- +4 more outcomes
Companies that use AxoGen
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
AxoGen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
AxoGen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA)coreAxoGen provides experienced coding assistance and Coverage Access Services through MCRA as consulting partner. MCRA staff provides guidance on CPT and ICD-10 codes, claim submission, benefits verification, pre-authorization assistance, and payer-specific pre-determination requests.
Scale indicators7 records
Recent moves8 records
Expansion highlights7 records
AxoGen competitors and assessment
Company assessmentBroad incumbents
- Stryker: Stryker is a diversified medical device incumbent with surgical, orthopedic, and neurotechnology portfolios that overlap with Axogen's extremity and reconstructive surgical call points. As a large incumbent, Stryker has the scale and R&D resources to enter the nerve repair space.
- Medtronic: Medtronic has a strong neurosurgery and ENT portfolio and active peripheral nerve stimulation offerings (e.g., Intellis, Vanta). It serves overlapping surgical specialists and could expand into nerve repair biologics from a position of strength.
- Cook Medical: Cook Medical sells a broad range of surgical implants and biologic devices (including the Biodesign SIS-based surgical products) that overlap with Axogen's porcine SIS-based Axoguard line in soft tissue and reconstructive surgery.
- Coloplast: Coloplast is a broad wound and skin care incumbent with Biatain and other advanced wound care products. While not a nerve repair specialist, it competes for surgical wound healing budgets and shares reimbursement-driven hospital channels with Axogen.
- ConvaTec: ConvaTec is a global wound and skin care company with advanced wound biologics (e.g., InnovaMatrix) that overlap with Axogen's Avive+ soft tissue matrix and compete for the same surgical reimbursement codes.
- Smith+Nephew: Smith+Nephew is a diversified incumbent with strong surgical and regenerative medicine franchises (including acquired Osiris cartilage and skin products) that overlap with Axogen's regenerative nerve and soft tissue repair products.
Emerging players
- Organogenesis: Organogenesis is a regenerative medicine company with leading skin substitute products (Apligraf, Dermagraft) targeting wound care and surgical applications adjacent to Axogen's nerve repair and Avive+ matrix portfolio.
- Vericel: Vericel is a regenerative medicine specialist (MACI, Epicel) targeting surgical and sports medicine indications. While focused on cartilage and burns, it uses a similar hospital-based specialty sales model and biologic reimbursement strategy to Axogen.
Direct peers
- MiMedx: MiMedx markets EpiFix and AmnioFix amniotic membrane allografts that directly overlap with Axogen's Avive+ Soft Tissue Matrix in surgical and wound applications. Both compete in regenerative soft tissue and use similar direct-to-surgeon field sales models.
- Integra LifeSciences: Integra is the most direct competitor in peripheral nerve repair, selling NeuraGen nerve guides and NeuraWrap/NeuraWrap+ protectors for nerve coaptation. Both companies target the same hand, plastic, and trauma surgeons with surgical nerve repair solutions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
AxoGen social profiles
Digital presenceAxoGen compliance and trust
Trust signalCompliance5 records
AxoGen financial estimates
Financial estimateRevenue estimate
Valuation estimate
AxoGen leadership team
Management profileNumber of profiles
Profiles12 records
AxoGen subsidiaries and ownership
Company hierarchySubsidiaries4 records
AxoGen funding detail
Funding detailFunding overview
Funding rounds12 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AxoGen M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AxoGen
What does AxoGen do?
AxoGen develops, manufactures, and markets a portfolio of medical devices and biologic products for the surgical repair of peripheral nerve injuries. Its offerings include the FDA-approved Avance acellular nerve allograft and the Axoguard family of porcine small intestine submucosa (SIS)-based nerve connectors, protectors, and caps, plus the Avive+ Soft Tissue Matrix. Products are sold to hospitals, ambulatory surgical centers, and surgeons for use in extremity, breast reconstruction, and oral maxillofacial/head & neck nerve repair procedures.
Is AxoGen a public or private company?
AxoGen is a public company. It is classified as public and is currently operating.
When was AxoGen founded?
AxoGen was founded in 2002. It employs 251 to 500 people.
Where is AxoGen based?
AxoGen is headquartered in Alachua, United States, in the North America region.
How does AxoGen make money?
One revenue line is on record: medical Device and Biologic Product Sales.
Who are AxoGen's main competitors?
Broad incumbents on record are Stryker, Medtronic, Cook Medical, Coloplast, ConvaTec and Smith+Nephew. Emerging players are Organogenesis and Vericel. Direct peers are MiMedx and Integra LifeSciences.
Does AxoGen have an API?
No public API is recorded for AxoGen.
What industry is AxoGen in?
AxoGen's product category is Surgical Nerve Repair Products. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 339112 and its SIC code is 3842.